Not recruiting
Anal squamous cell carcinoma+4
Not recruitingStudy of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas
Registered drugNo placebo
Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas
Registered drugNo placebo
- Disease:Anal squamous cell carcinomaSquamous cell carcinoma of head and neck+3
- Substances:PembrolizumabVorinostat
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
